Comparison of different antibodies for detection of progesterone receptor in breast cancer

Press, Michael F.; Spaulding, Betsy O.; Groshen, Susan; Kaminsky, David B.; Hagerty, Margaret; Sherman, Lori; Christensen, Kurt D.; Edwards, Dean P.

doi:10.1016/s0039-128x(02)00039-9

Cited by 76 publications

(62 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mouse monoclonal antibodies (mAbs) to human PR (AB52 and N559) that detect an epitope in the NTD common to PR-A and PR-B have been previously described (39,40). Antibody to SRC-1 (sc-6098) was obtained from Santa Cruz Biotechnology, Inc., and is qualified for immunoprecipitation and immunoblot assays.…”

Section: Methodsmentioning

confidence: 99%

Regulation of the Structurally Dynamic N-terminal Domain of Progesterone Receptor by Protein-induced Folding

Kumar

Moure²,

Khan

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background:The mechanism of action of the N-terminal domain (NTD) of the progesterone receptor is not well understood. Results: We show the PR NTD adopts a functional folded conformation by undergoing disorder-order transition via binding to a target protein, TBP. Conclusion: This structural reorganization of the NTD facilitates binding of co-activators required for transcriptional activation. Significance: A novel mechanism of PR-dependent transcriptional activation is defined.

show abstract

Section: Methodsmentioning

confidence: 99%

Regulation of the Structurally Dynamic N-terminal Domain of Progesterone Receptor by Protein-induced Folding

Kumar

Moure²,

Khan

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…For interpretation of staining patterns using 10H8 antibody, 80% of breast cancer case patients with 2+ membrane staining of tumor cells and 99% of 3+ membrane staining have been shown to demonstrate HER-2 gene amplification (55). Therefore, breast cancers with either 2+ or 3+ membrane staining on malignant cells were considered as positive for overexpression of HER-2/neu.…”

Section: Laboratory Methodsmentioning

confidence: 99%

Serum organochlorines and breast cancer: a case–control study among African-American women

Gatto

Longnecker

Press

et al. 2007

Cancer Causes Control

View full text Add to dashboard Cite

This population-based case-control study of African-American women (355 breast cancer case patients, 327 controls) examined the association between breast cancer and circulating levels of PCBs and dichlorodiphenyldichloroethene (DDE), a metabolite of DDT. Case patients were diagnosed with invasive breast carcinoma and interviewed between June 1995 and July 1998, and control subjects were identified by random digit dialing methods. Serum levels of DDE and total PCBs were adjusted for total lipid content. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable unconditional logistic regression methods. Effect modification by tumor receptor status and cancer treatment was investigated. Breast cancer risk was not associated with increasing quintiles of lipid-adjusted PCBs or DDE (highest vs. lowest quintile adjusted for age, body mass index (BMI) and breastfeeding for DDE: OR=1.02, 95% CI=(0.61, 1.72), p-trend = 0.74; for PCBs: OR=1.01, 95% CI=(0.63, 1.63), p-trend = 0.56). Risk did not differ by strata of BMI, breastfeeding, parity, menopausal status or tumor receptor status. This study, the largest study of African-American women to date, does not support a role of DDE and total PCBs in breast cancer risk at the levels measured.

show abstract

“…Although there are vocal proponents of both methods, many studies have shown that, when properly performed, there is a very strong correlation between IHC and FISH, 8,15,29,30 and that they are equivalent (and sometimes complimentary) in clinical utility.…”

Section: Her2 Oncogene/oncoproteinmentioning

confidence: 99%

Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

2010

View full text Add to dashboard Cite

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERa), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERa, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.

show abstract

Comparison of different antibodies for detection of progesterone receptor in breast cancer

Cited by 76 publications

References 50 publications

Regulation of the Structurally Dynamic N-terminal Domain of Progesterone Receptor by Protein-induced Folding

Regulation of the Structurally Dynamic N-terminal Domain of Progesterone Receptor by Protein-induced Folding

Serum organochlorines and breast cancer: a case–control study among African-American women

Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

Contact Info

Product

Resources

About